Spinocerebellar ataxia type 28 (SCA28) is an autosomal dominant neurodegenerative disorder caused by missense AFG3L2 mutations. To examine the occurrence of SCA28 in the Czech Republic, we screened 288 unrelated ataxic patients with hereditary (N = 49) and sporadic or unknown (N = 239) form of ataxia for mutations in exons 15 and 16, the AFG3L2 mutation hotspots. A single significant variant, frameshift mutation c.1958dupT leading to a premature termination codon, was identified in a patient with slowly progressive speech and gait problems starting at the age of 68 years. Neurological examination showed cerebellar ataxia, mild Parkinsonian features with predominant bradykinesia, polyneuropathy of the lower limbs, and cognitive decline. However, other common SCA28 features like pyramidal tract signs (lower limb hyperreflexia, positive Babinski sign), ophthalmoparesis or ptosis were absent. The mutation was also found in a patient's unaffected daughter in whom a targeted examination at 53 years of age revealed mild imbalance signs. RNA analysis showed a decreased ratio of the transcript from the mutated AFG3L2 allele relative to the normal transcript in the peripheral lymphocytes of both patients. The ratio was increased by puromycin treatment, indicating that the mutated transcript can be degraded via nonsense-mediated RNA decay. The causal link between the mutation and the phenotype of the patient is currently unclear but a pathogenic mechanism based on AFG3L2 haploinsufficiency rather than the usual dominant-negative effect of missense AFG3L2 mutations reported in SCA28, cannot be excluded.

Department of Biology and Medical Genetics Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

See more in PubMed

Cell. 1998 Jun 12;93(6):973-83 PubMed

Mol Cell Biol. 2007 Jan;27(2):758-67 PubMed

Brain. 2012 Oct;135(Pt 10):2994-3004 PubMed

Hum Mutat. 2010 Oct;31(10):1117-24 PubMed

J Neurosci. 2009 Jul 22;29(29):9244-54 PubMed

Ann Neurol. 2012 Dec;72(6):870-80 PubMed

Genomics. 1999 Jul 1;59(1):51-8 PubMed

Brain. 2006 Jan;129(Pt 1):235-42 PubMed

Brain. 2012 Oct;135(Pt 10):2980-93 PubMed

Hum Mol Genet. 2012 Sep 1;21(17):3858-70 PubMed

EMBO J. 2008 Jan 23;27(2):306-14 PubMed

Orphanet J Rare Dis. 2008 Feb 19;3:4 PubMed

Hum Mutat. 2009 Sep;30(9):1355-64 PubMed

PLoS Genet. 2011 Oct;7(10):e1002325 PubMed

BMB Rep. 2013 Jan;46(1):9-16 PubMed

Ann Neurol. 2012 Dec;72(6):859-69 PubMed

Cerebellum. 2012 Dec;11(4):821-7 PubMed

Nature. 2009 Aug 20;460(7258):1011-5 PubMed

Nat Rev Mol Cell Biol. 2012 Nov;13(11):700-12 PubMed

Nat Genet. 2010 Apr;42(4):313-21 PubMed

Cell. 2005 Oct 21;123(2):277-89 PubMed

J Clin Invest. 2012 Nov;122(11):4048-58 PubMed

Cerebellum. 2008;7(2):184-8 PubMed

Eur J Hum Genet. 2010 Aug;18(8):965-8 PubMed

Analysis of 31-year-old patient with SYNGAP1 gene defect points to importance of variants in broader splice regions and reveals developmental trajectory of SYNGAP1-associated phenotype: case report